The 0.25mg to 2.4mg titration schedule represents the optimal balance identified through these extensive research programs
What is reasonable to monitor Weight and waist circumference Trial endpoints
10.4% of patients treated with SAXENDA and no patients treated with placebo discontinued treatment due to an adverse reaction [see ADVERSE REACTIONS ]
For Weight Loss FDA-approved for weight management, Ozempic, Wegovy ( Semaglutide ) and Mounjaro, Zepbound ( Tirzepatide ) are suitable for adults with a BMI 30, or BMI 27 with at least one obesity-related condition, such as high blood pressure, high cholesterol, or type 2 diabetes
This is the second step on the dose escalation ladder, typically prescribed during weeks five through eight
Pharmaceutical secondary standards for application in quality control, provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards